{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:27:06Z","timestamp":1793327226682,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.atherosclerosis.2024.117560","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T21:20:05Z","timestamp":1713820805000},"page":"117560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The current landscape for diabetes treatment: Preventing diabetes-associated CV risk"],"prefix":"10.1016","volume":"394","author":[{"given":"Angela","family":"Dardano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Garofolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5388-0270","authenticated-orcid":false,"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.117560_bib1","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.3390\/ijms23063346","article-title":"Pathophysiology of atherosclerosis","volume":"23","author":"Jebari-Benslaiman","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2024.117560_bib2","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"GBD-NHLBI-JACC global Burden of cardiovascular diseases Writing group. Global Burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.117560_bib4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9131","key":"10.1016\/j.atherosclerosis.2024.117560_bib5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.117560_bib6","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00125-009-1352-5","article-title":"Megatrials in type 2 diabetes. From excitement to frustration?","volume":"52","author":"Del Prato","year":"2009","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.117560_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 3","key":"10.1016\/j.atherosclerosis.2024.117560_bib8","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.2337\/diabetes.53.suppl_3.S39","article-title":"Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis","volume":"53","author":"Gaede","year":"2004","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.117560_bib9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jama.2019.14533","article-title":"Sulfonylureas and cardiovascular safety: the final Verdict?","volume":"322","author":"Wexler","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.117560_bib10","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.numecd.2022.03.007","article-title":"SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes. Effects of insulin on cardiovascular events and all-cause mortality in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"32","author":"Mannucci","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/dmrr.790","article-title":"Thiazolidinediones as anti-inflammatory and anti-atherogenic agents","volume":"24","author":"Ceriello","year":"2008","journal-title":"Diabetes Metab Res Rev"},{"issue":"9493","key":"10.1016\/j.atherosclerosis.2024.117560_bib12","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12933-022-01575-9","article-title":"Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes","volume":"21","author":"Davies","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2024.117560_bib14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.117560_bib15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10193","key":"10.1016\/j.atherosclerosis.2024.117560_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.atherosclerosis.2024.117560_bib17","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"SELECT trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117560_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"10365","key":"10.1016\/j.atherosclerosis.2024.117560_bib19","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.117560_bib20","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A Consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metabol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.117560_bib22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.tem.2019.07.004","article-title":"Heterogeneity and Similarities in GLP-1 receptor agonist cardiovascular outcomes trials","volume":"30","author":"Caruso","year":"2019","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.117560_bib23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","article-title":"Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management","volume":"7","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.117560_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0289616","article-title":"The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"18","author":"Liao","year":"2023","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.117560_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13574","article-title":"GLP-1 analogs and regional adiposity: a systematic review and meta-analysis","volume":"24","author":"Akoumianakis","year":"2023","journal-title":"Obes. Rev."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","article-title":"Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"110","author":"Sun","year":"2015","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.117560_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210164","article-title":"Novel Antidiabetic agents and their effects on lipid profile: a Single Shot for several cardiovascular targets","volume":"24","author":"Piccirillo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.117560_bib29","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00592-023-02154-4","article-title":"Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis","volume":"60","author":"Diallo","year":"2023","journal-title":"Acta Diabetol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.117560_bib30","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/obr.12755","article-title":"Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms","volume":"19","author":"Lee","year":"2018","journal-title":"Obes. Rev."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13098-023-01085-y","article-title":"Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Wang","year":"2023","journal-title":"Diabetol Metab Syndr"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.117560_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108558","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: an updated meta-analysis of randomized controlled trials","volume":"37","author":"Jin","year":"2023","journal-title":"J. Diabet. Complicat."},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105068","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials","volume":"160","author":"S\u00e1nchez-Garc\u00eda","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.117560_bib34","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2337\/dc21-0076","article-title":"The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58","volume":"44","author":"Mosenzon","year":"2021","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.117560_bib35","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.2337\/dc22-0382","article-title":"Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial","volume":"45","author":"Mosenzon","year":"2022","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.117560_bib36","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.117560_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112394","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity","volume":"9","author":"Oelze","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12933-018-0750-8","article-title":"Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury","volume":"17","author":"Aroor","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173040","article-title":"Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice","volume":"875","author":"Ganbaatar","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","article-title":"SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob-\/- mice","volume":"18","author":"Adingupu","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"issue":"1\u20132","key":"10.1016\/j.atherosclerosis.2024.117560_bib41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11010-019-03555-2","article-title":"Empagliflozin restores the integrity of the endothelial glycocalyx in vitro","volume":"459","author":"Cooper","year":"2019","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104781","article-title":"Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium","volume":"157","author":"Cappetta","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1479164117733626","article-title":"Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis","volume":"15","author":"Gaspari","year":"2018","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib44","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6305735","article-title":"The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE-\/- mice","volume":"2016","author":"Leng","year":"2016","journal-title":"Mediat. Inflamm."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12933-018-0708-x","article-title":"SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice","volume":"17","author":"Lee","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib46","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-018-0749-1","article-title":"Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice","volume":"17","author":"Nasiri-Ansari","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.117560_bib47","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.3390\/ijms23105634","article-title":"Role of sodium-glucose Co-transporter 2 inhibitors in the regulation of inflammatory processes in Animal models","volume":"23","author":"Feij\u00f3o-Band\u00edn","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1008922","article-title":"Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials","volume":"9","author":"Scisciola","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib49","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2023.03.011","article-title":"Empagliflozin ameliorates atherosclerosis via regulating the intestinal flora","volume":"371","author":"Hao","year":"2023","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.117560_bib50","doi-asserted-by":"crossref","first-page":"644","DOI":"10.5551\/jat.50807","article-title":"Empagliflozin's ameliorating effect on Plasma triglycerides: Association with endothelial function Recovery in diabetic patients with coronary artery disease","volume":"27","author":"Sawada","year":"2020","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13098-018-0395-5","article-title":"Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance","volume":"10","author":"Hattori","year":"2018","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib52","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12933-019-0839-8","article-title":"How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial","volume":"18","author":"Bosch","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12933-022-01463-2","article-title":"The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)","volume":"21","author":"Omar","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.117560_bib54","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/dom.14639","volume":"24","author":"Antlanger","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib55","article-title":"Effects of dapagliflozin and Sitagliptin on insulin resistant and body fat distribution in newly diagnosed type 2 diabetic patients","volume":"26","author":"Sun","year":"2020","journal-title":"Med Sci Monit"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.117560_bib56","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/dom.14363","article-title":"Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: a randomized, placebo-controlled, exploratory study","volume":"23","author":"Oldgren","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.curtheres.2017.07.002","article-title":"Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study","volume":"87","author":"Tobita","year":"2017","journal-title":"Curr. Ther. Res. Clin. Exp."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.117560_bib58","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/bcp.13903","article-title":"Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study","volume":"85","author":"Phrommintikul","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib59","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-021-01264-z","article-title":"Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial","volume":"20","author":"Sposito","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib60","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvz017","article-title":"Effects of dapagliflozin on endothelial dysfunction in type 2 diabetes with established Ischemic heart disease (EDIFIED)","volume":"4","author":"Zainordin","year":"2019","journal-title":"J Endocr Soc"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib61","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12933-019-0877-2","article-title":"Canagliflozin for Japanese patients with chronic heart failure and type II diabetes","volume":"18","author":"Sezai","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12902-022-00949-0","article-title":"Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes","volume":"22","author":"Hao","year":"2022","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib63","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.117560_bib64","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1089\/dia.2018.0169","article-title":"Effect of canagliflozin on Urinary albumin excretion in Japanese patients with type 2 diabetes mellitus and Microalbuminuria: a pilot study","volume":"20","author":"Osonoi","year":"2018","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117560_bib65","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"13","key":"10.1016\/j.atherosclerosis.2024.117560_bib66","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.3390\/jcm12134458","article-title":"Empagliflozin reduces Interleukin-6 levels in patients with heart failure","volume":"12","author":"Gotzmann","year":"2023","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.117560_bib67","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin Sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.117560_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107590","article-title":"Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - a double blind randomized placebo-controlled crossover trial","volume":"34","author":"Eickhoff","year":"2020","journal-title":"J. Diabet. Complicat."},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib69","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.diabres.2019.01.029","article-title":"Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus","volume":"149","author":"Koike","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.117560_bib70","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jgh.15580","article-title":"The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"36","author":"Phrueksotsai","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.117560_bib72","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.3390\/pharmaceutics15071858","article-title":"Incretins-based Therapies and their cardiovascular effects: new Game-Changers for the management of patients with diabetes and cardiovascular disease","volume":"15","author":"Bernardini","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib73","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2013.10.025","article-title":"Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells","volume":"232","author":"Batchuluun","year":"2014","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.117560_bib74","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.2337\/db14-0976","article-title":"Exenatide Protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in Humans","volume":"64","author":"Koska","year":"2015","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.117560_bib75","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10557-013-6463-z","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation","volume":"27","author":"Dai","year":"2013","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib76","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.abb.2019.07.008","article-title":"Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation","volume":"671","author":"Luo","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.117560_bib77","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00592-020-01551-3","article-title":"Exendin-4 reverses high glucose-induced endothelial progenitor cell dysfunction via SDF-1\u03b2\/CXCR7-AMPK\/p38-MAPK\/IL-6 axis","volume":"57","author":"Yang","year":"2020","journal-title":"Acta Diabetol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117560_bib78","doi-asserted-by":"crossref","first-page":"C164","DOI":"10.1152\/ajpcell.00249.2014","article-title":"Exendin-4 promotes endothelial barrier enhancement via PKA- and Epac1-dependent Rac1 activation","volume":"308","author":"Li","year":"2015","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib79","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (Glucagon-Like peptide-1) receptor Mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Helmst\u00e4dter","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib80","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.molimm.2019.09.021","article-title":"Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: an implication in the treatment of atherosclerosis","volume":"116","author":"Chang","year":"2019","journal-title":"Mol. Immunol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.117560_bib81","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/cells8060589","article-title":"Liraglutide inhibits endothelial-to-mesenchymal transition and attenuates neointima formation after endovascular injury in streptozotocin-induced diabetic mice","volume":"8","author":"Tsai","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib82","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12933-015-0177-4","article-title":"Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1\/2 and PI3K\/Akt signaling pathways","volume":"14","author":"Shi","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.117560_bib83","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2337\/db15-1141","article-title":"Glucagon-like peptide 1 receptor activation attenuates platelet aggregation and thrombosis","volume":"65","author":"Cameron-Vendrig","year":"2016","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.117560_bib84","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/bph.13549","article-title":"Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice","volume":"174","author":"Steven","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib85","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12933-017-0626-3","article-title":"Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","volume":"16","author":"Bruen","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib86","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.peptides.2013.12.015","article-title":"A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis","volume":"54","author":"Tashiro","year":"2014","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117560_bib87","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"SOLOIST-WHF trial Investigators. Sotagliflozin in patients with diabetes and recent Worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117560_bib88","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib89","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.117560_bib90","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.117560_bib91","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.117560_bib92","doi-asserted-by":"crossref","first-page":"213","DOI":"10.12997\/jla.2023.12.3.213","article-title":"The cardiovascular effect of tirzepatide: a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist","volume":"12","author":"Cho","year":"2023","journal-title":"J Lipid Atheroscler"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.117560_bib93","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to Titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.117560_bib94","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.117560_bib95","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117560_bib96","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/dom.14553","article-title":"The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis","volume":"24","author":"Wilson","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117560_bib97","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.cmet.2017.11.003","article-title":"Inactivation of the glucose-dependent insulinotropic polypeptide receptor improves outcomes following experimental myocardial infarction","volume":"27","author":"Ussher","year":"2018","journal-title":"Cell Metabol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.117560_bib98","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.2337\/db21-0103","article-title":"Genetically Predicted glucose-dependent insulinotropic polypeptide (GIP) levels and cardiovascular disease risk are Driven by Distinct causal variants in the GIPR region","volume":"70","author":"Bowker","year":"2021","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117560_bib99","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.cmet.2017.11.003","article-title":"Inactivation of the glucose-dependent insulinotropic polypeptide receptor improves outcomes following experimental myocardial infarction","volume":"27","author":"Ussher","year":"2018","journal-title":"Cell Metabol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.117560_bib100","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00125-011-2241-2","article-title":"Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice","volume":"54","author":"Nagashima","year":"2011","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.117560_bib101","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1210\/en.2018-00336","article-title":"Glucose-dependent insulinotropic polypeptide suppresses peripheral arterial remodeling in Male mice","volume":"159","author":"Mori","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am. Heart J."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.117560_bib103","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.atherosclerosis.2024.117560_bib104","article-title":"What is the pipeline for future medications for obesity?","author":"Melson","year":"2024","journal-title":"Int. J. Obes."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.117560_bib105","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jacc.2023.05.048","article-title":"GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes","volume":"82","author":"Neves","year":"2023","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024001205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024001205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:28:20Z","timestamp":1762187300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915024001205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":105,"alternative-id":["S0021915024001205"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117560","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The current landscape for diabetes treatment: Preventing diabetes-associated CV risk","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117560"}}